Solid tumor biology has become a critical step in accessing the potency of many cancer drugs. 3D spheroids and organoids can provide measurements such as size differences under drug conditions or metabolism and diffusion rates critical to drug development.
For the development of new drugs and the advancement of new cell therapies, pharmaceutical companies have recurred to cytotoxicity assays as a quick way to assess the viability of cell lines in response to an external stimulus.
The development of targeted molecular therapies is an increasingly popular approach to combat and overcome the limitations of conventional treatments.
A fundamental understanding of the molecular mechanisms responsible for the development and progression of RCC will be pivotal in developing next-generation treatment protocols to improve patient outcomes.
Because there is no certified reference material to determine cell concentration, ISO cell counting standards are a valuable tool for evaluating and selecting fit-for-purpose cell counting methods.
The ongoing pursuit of novel anti-cancer therapeutics must consider the potential for off-target effects on the immune system.
The researchers in this study first utilized various techniques to explore the role of MEX3A in glioma, including immunohistochemistry to assess MEX3A expression levels in glioma tissues, knockdowns of MEX3A in conjunction with a transwell assay to assess migration and an in-vivo mouse model of tumor burden.
The severe acute respiratory coronavirus 2 (SARS-CoV-2) has caused the ongoing COVID-19 pandemic, infecting more than 206 million people and causing upwards of 4.34 million deaths at the time of writing.
View this demo on-demand and discover a better way to count cells with the next-generation high-throughput cell counter!
Establishing a High-throughput Screening Platform for NK mediated Cytotoxicity using Image Cytometry
Researchers highlight the need for large-scale screening of cytotoxic cells and their ability to kill target cell lines in both a 2D and 3D fashion.